Published in Cardiovascular Device Liability Week, October 28th, 2007
"It has been demonstrated that 6-thio-GTP, a metabolite of azathioprine, specifically inhibits Vav1-Rac activity in T lyrnpliocytes. Here we show the immunosuppressive efficacy of 6-thio-GTP in the prevention of cardiac allograft rejection. T cell proliferations were measured by H-3-thymidine uptake. The immunosuppressive activities of 6-tliio-GTP were tested in the cardiac allograft model of C57BL/6...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.